On January 3, 2020, Ever Supreme passed evaluation of “A + Industrial Innovation R&D Program” on the “Phase II Clinical Trial Project of Dendritic Cell Vaccine Treatment for Malignant Brain Tumors”. The Company had once again made an achievement. We believe that in the near future, cellular drugs can be widely used in those patients in need.
(1).jpg)